Indeed, pharmacological blockade of peripheral cannabinoid subtype-1 receptors (CB1Rs) reduces food intake and improves metabolic dysfunction associated with obesity in rodents similarly to brain-penetrant CB1R antagonists [21,23,24,27,28,29,30,37]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.